TAPI NL B.V. (TAPI)

Overview

TAPI NL B.V. is the Amsterdam-based entity of TAPI (Teva Active Pharmaceutical Ingredients), which runs API manufacturing and R&D sites in Europe, Asia and the Americas. TAPI offers peptide development and manufacturing, including GLP-1 analogues such as semaglutide and tirzepatide, as both catalogue APIs and CDMO work. TAPI NL holds active US Type II DMFs for Bivalirudin, Desmopressin, Eptifibatide, Exenatide, Icatibant, Linaclotide, Octreotide, Semaglutide, Tirzepatide. TAPI publishes regulator inspection outcomes, including USFDA and PMDA inspections rated acceptable.

Capabilities

• Peptide API manufacturing
• Peptide CDMO
• Fermentation
• GLP-1 process development
• Global multi-site supply

Quality signals

Sources

• tapi.com/
• tapi.com/segment/peptides/
• tapi.com/about-us/
• tapi.com/site-inspections/
• fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs
• en.globes.co.il/en/article-teva-to-lay-off-250-in-api-division-in-israel-1001545492
• google.com/finance/quote/TEVA:NYSE